NFGH
TNGX icon

Nan Fung Group Holdings’s Tango Therapeutics TNGX Stock Holding History

Nan Fung Group Holdings’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,500
Closed -$279K – 56
2021
Q4 		$279K Buy
+25,500
New +$307K 0.08% 40

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Nan Fung Group Holdings's TNGX Position: Q1 2022 in Review

Nan Fung Group Holdings sold out of Tango Therapeutics (TNGX) in Q1 2022, closing a stake of 25,500 shares — an estimated $279K sold.

Nan Fung Group Holdings first reported a position in TNGX in Q4 2021 and held it in 1 quarter. The position peaked at $279K in Q4 2021. 72 funds tracked by Wall St. Rank hold TNGX as of Q1 2022.

  • Nan Fung Group Holdings reported no remaining Tango Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Nan Fung Group Holdings sold 25,500 Tango Therapeutics shares in Q1 2022, an estimated $279K.
  • Nan Fung Group Holdings first reported a position in Tango Therapeutics in Q4 2021 and held it in 1 quarter.
  • Nan Fung Group Holdings's Tango Therapeutics position peaked at $279K in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2022.

Based on Nan Fung Group Holdings's 13F filing for Q1 2022, filed 13 May 2022.